Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Hema Vankayala"'
Publikováno v:
Cureus.
Autor:
Brenda Dickow, Ulka N. Vaishampayan, William O. Quarshie, Kendra Schwartz, Fawn D. Vigneau, Supraja Chalasani, Hema Vankayala
Publikováno v:
Clinical Genitourinary Cancer. 12:124-129
Introduction With the advent and availability of targeted therapy, the treatment of advanced/metastatic renal cell carcinoma (RCC) underwent a drastic change in 2005. The effect of this change on clinical outcome within the population has not been st
Publikováno v:
American Journal of Cardiovascular Drugs. 7:75-79
BACKGROUND Aldosterone antagonists have been proven to be beneficial in severe heart failure (HF) as a result of systolic dysfunction. We sought to determine if there is a disparity in their utilization compared with ACE inhibitors and beta-adrenocep
Publikováno v:
Renal Cell Carcinoma ISBN: 9781461423997
Germline mutations in c-met proto-oncogene contribute to development of papillary renal carcinomas. C-met encodes a receptor tyrosine kinase, and it controls genetic programs leading to cell growth, invasion, and protection from apoptosis. Hepatocyte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::847e18636008fc68d886f8230c4a999f
https://doi.org/10.1007/978-1-4614-2400-0_10
https://doi.org/10.1007/978-1-4614-2400-0_10
Publikováno v:
Kidney Cancer ISBN: 9783642218576
Renal cell cancer (RCC) accounts for 2–3% of adult malignancies, and the incidence appears to be rising each year. Cigarette smoking, obesity, and hypertension are contributing risk factors, among others. Clear cell RCC is the most common histologi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::87d51c0e46b418b210f83443eed3cb1d
https://doi.org/10.1007/978-3-642-21858-3_5
https://doi.org/10.1007/978-3-642-21858-3_5
Autor:
Hema Vankayala, Ulka N. Vaishampayan
Publikováno v:
Oncology & Hematology Review (US). 11:58
The face of metastatic prostate cancer (PC) has been remarkably reshaped with the current advances in its management. Kudos to the cuttingedge research that has pinpointed new targets and agents. The main stumbling block in this disease is progressio
Autor:
Ulka N. Vaishampayan, Hema Vankayala
Publikováno v:
Oncology & Hematology Review (US). 10:123
Prostate cancer (PC) is the second leading cause of cancer-related death in men in the US. Biochemical relapse is a significant problem, due to the eventual progression to metastatic disease. It is also an opportunity to explore interventions that ma
Autor:
Daryn Smith, Ulka N. Vaishampayan, Hyun J. Bang, Lance K. Heilbrun, Brenda Dickow, Hema Vankayala, Peter Litrup, B. Adam
Publikováno v:
Journal of Clinical Oncology. 30:e15081-e15081
e15081 Background: Resection of metastasis in renal cancer (mRCC) yields 5-year survival rates of 20% to 30%. Yet most patients (pts) poor surgical candidates or have unresectable disease. Percutaneous cryoablation is a minimally invasive procedure e